Tesamorelin
Also known as: Egrifta, Egrifta SV, Egrifta WR
An FDA-approved growth hormone-releasing factor analog, currently the only medication approved in the U.S. specifically for reducing excess belly fat in adults with HIV-associated lipodystrophy. Also widely used off-label for body composition and anti-aging.
How it works
Tesamorelin is a synthetic version of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to produce and release your own natural growth hormone, which then helps break down visceral (belly) fat. Unlike injectable HGH, it works through your body's own feedback loop.
Common uses
- HIV-associated lipodystrophy (FDA-approved indication)
- Visceral fat reduction (off-label)
- Growth hormone optimization (off-label)
- Body composition improvement
- Cognitive support (studied in mild cognitive impairment)
Side effects
- Joint pain (arthralgia)
- Injection site reactions (redness, itching, swelling)
- Pain in arms or legs
- Peripheral edema (swelling)
- Muscle pain (myalgia)
- Numbness or tingling in hands
- Possible increase in blood sugar
Key research
- Phase 3 trials showed significant reduction in trunk fat (visceral adipose tissue) in HIV patients with lipodystrophy
- Studies demonstrated increased lean body mass and improved lipid profiles
- FDA approved new Egrifta WR formulation in March 2025, requiring reconstitution only once per week instead of daily
Safety notes
- FDA-approved only for HIV-associated lipodystrophy, not for general weight loss
- Insurance typically covers it only for the approved indication
- Should not be used in people with active cancer due to growth hormone stimulation
- Requires monitoring of IGF-1 levels and blood sugar
Too many clinics, not enough clarity?
We don't sell peptides. Tell us your goals and we'll connect you with a vetted provider who can figure out what actually makes sense for you.
See what's right for youExplore other peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. One of the most well-studied peptides available.
Tirzepatide
A dual GIP/GLP-1 receptor agonist that has shown even greater weight loss results than semaglutide in head-to-head trials.
BPC-157
A synthetic peptide derived from human gastric juice, studied primarily in animal models for its regenerative and anti-inflammatory properties. Not FDA-approved.
CJC-1295 / Ipamorelin
A commonly paired combination of growth hormone-releasing peptides used to stimulate natural GH production for anti-aging, body composition, and recovery.